Pyxis Oncology Inc (PYXS) 14-day ATR is 0.20: This Stock is Set to Soar Above its Peers

Pyxis Oncology Inc (NASDAQ: PYXS) flaunted slowness of -4.19% at $1.60, before settling in for the price of $1.67 at the close. Taking a more long-term approach, PYXS posted a 52-week range of $1.49-$6.85.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 0.00%. Meanwhile, its Annual Earning per share during the time was -118.72%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 41.34%. This publicly-traded company’s shares outstanding now amounts to $59.45 million, simultaneously with a float of $41.13 million. The organization now has a market capitalization sitting at $91.16 million. At the time of writing, stock’s 50-day Moving Average stood at $2.8964, while the 200-day Moving Average is $3.6418.

Pyxis Oncology Inc (PYXS) Ownership Facts and Figures

Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Pyxis Oncology Inc industry. Pyxis Oncology Inc’s current insider ownership accounts for 30.83%, in contrast to 54.00% institutional ownership. According to the most recent insider trade that took place on Nov 26 ’24, this organization’s CFO & COO bought 88,850 shares at the rate of 1.96, making the entire transaction reach 174,364 in total value, affecting insider ownership by 1,199,143.

Pyxis Oncology Inc (PYXS) Earnings and Revenue Records

Pyxis Oncology Inc’s EPS increase for this current 12-month fiscal period is 41.34% and is forecasted to reach -1.30 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 34.60% through the next 5 years, which can be compared against the -118.72% growth it accomplished over the previous five years trading on the market.

Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators

Let’s observe the current performance indicators for Pyxis Oncology Inc (PYXS). It’s Quick Ratio in the last reported quarter now stands at 7.33. The Stock has managed to achieve an average true range (ATR) of 0.20. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.64.

In the same vein, PYXS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.05, a figure that is expected to reach -0.32 in the next quarter, and analysts are predicting that it will be -1.30 at the market close of one year from today.

Technical Analysis of Pyxis Oncology Inc (PYXS)

Now, what If we examine the latest scores posted by [Pyxis Oncology Inc, PYXS]. During the last 5-days, its volume was better the volume of 0.79 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 66.54% While, its Average True Range was 0.1675.

Raw Stochastic average of Pyxis Oncology Inc (PYXS) in the period of the previous 100 days is set at 2.82%, which indicates a major fall in contrast to 33.33% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 81.82% that was lower than 119.23% volatility it exhibited in the past 100-days period.